Ethics of Continuing to Provide a Drug on an Open-Label Extension Study for an “Unapproved Indication”

Author： Taylor Holly A.   Kuwana Ellen   Wilfond Benjamin S.  

Publisher： Routledge Ltd

ISSN： 1536-0075

Source： American Journal of Bioethics, Vol.14, Iss.4, 2014-04, pp. : 56-56

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

The Role of Clinical Equipoise and Practical Considerations in Deciding Whether to Continue to Provide a Drug on an Open-Label Extension Study for an “Unapproved Indication”

By Nash Ryan R.  

American Journal of Bioethics, Vol. 14, Iss. 4, 2014-04 ,pp. : 59-60

Routledge Ltd

Access to resources Recommend Favorite

When Should Open-Label Extension Studies Be Stopped?

By Crites Joshua S.  

American Journal of Bioethics, Vol. 14, Iss. 4, 2014-04 ,pp. : 57-58

Routledge Ltd

Access to resources Recommend Favorite

Open-Label Extension Studies: Are They Really Research?

By Cho Mildred K.  

American Journal of Bioethics, Vol. 14, Iss. 4, 2014-04 ,pp. : 60-61

Routledge Ltd

Access to resources Recommend Favorite

The Relevance of Research Study Phase to Disclosure of Off-Label Drug Availability

By Baskaran Amrutha   Sade Robert M.  

American Journal of Bioethics, Vol. 14, Iss. 4, 2014-04 ,pp. : 53-54

Routledge Ltd

Access to resources Recommend Favorite

The History of Medical Ethics Is Crucial for a Critical Perspective in the Continuing Development of Ethics Consultation

By McCullough Laurence B.  

American Journal of Bioethics, Vol. 1, Iss. 4, 2001-12 ,pp. : 55-57

Routledge Ltd

Access to resources Recommend Favorite